Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.


AIM OF THE STUDY As a rise in mean corpuscular volume (MCV) of the erythrocyte is frequently seen during treatment with imatinib and sunitinib, we investigated whether macrocytosis (MCV > 100 fl) also occurs as a class effect in other tyrosine kinase inhibitors (TKIs) and whether occurrence of macrocytosis is associated with outcome. MATERIALS AND METHODS In 533 patients, using 5 TKIs, we investigated if macrocytosis and an increase in MCV were associated with progression-free survival and overall survival (OS) in specific tumour-treatment combinations. RESULTS Macrocytosis as well as an increase in MCV from baseline of >10 fl (ΔMCV +10 fl), when included as a time-dependent covariate, were associated with improved OS in patients with renal cell cancer (RCC) treated with sunitinib (macrocytosis, hazard ratio [HR] = 0.61, p = 0.031, and ΔMCV +10 fl, HR = 0.58, p = 0.016). CONCLUSION In sunitinib-treated patients with RCC, the occurrence of macrocytosis, or a substantial increase in MCV levels after start of treatment, could potentially serve as a positive prognostic factor for survival, if validated prospectively.

DOI: 10.1016/j.ejca.2015.12.019
Citations per Year

Citation Velocity: 12

Averaging 12 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Kloth2016MacrocytosisAA, title={Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.}, author={Jacqueline S. L. Kloth and Paul Hamberg and Pauline A J Mendelaar and Roderick R Dulfer and Bronno van der Holt and Karel Eechoute and Erik A C Wiemer and Wim H. J. Kruit and Stefan Sleijfer and Ron H . J . Mathijssen}, journal={European journal of cancer}, year={2016}, volume={56}, pages={101-6} }